Osteochondritis Dissecans Clinical Trials

Find Osteochondritis Dissecans Clinical Trials Near You

A Prospective, Open-label, Randomized, Concurrent Active-controlled, Longitudinal, Multicenter, Phase 3 Clinical Study of the Safety and Efficacy of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee

Who is this study for? Patients aged 10 to 17 years with symptomatic chondral or osteochondral defects of the knee due to osteochondritis dissecans or acute trauma
Status: Recruiting
Location: See all (12) locations...
Intervention Type: Procedure, Biological
Study Type: Interventional
Study Phase: Phase 3
SUMMARY

The objective of this study is to compare the efficacy and safety of MACI® vs arthroscopic microfracture in the treatment of participants aged 10 to 17 years with symptomatic articular chondral or osteochondral defects of the knee.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 10
Maximum Age: 17
Healthy Volunteers: f
View:

• Symptomatic cartilage or osteochondral defects

• One or more International Cartilage Repair Society (ICRS) Grade III or IV chondral or unsalvageable osteochondral defects located on the femoral condyles and/or trochlea amenable to treatment with the surgical procedure determined at randomization (MACI or microfracture).

‣ Concurrent ICRS Grade I and II defects are acceptable on the tibia if they remain untreated (or are treated with debridement only) at the time of study treatment.

⁃ Participants with a potentially re-attachable osteochondral fragment, identified by magnetic resonance imaging (MRI) and that has not previously been repaired, may be consented to the study and undergo baseline assessments per protocol and prior to confirmatory arthroscopy (Visit 2). At arthroscopy, an attempt will be made to reattach the osteochondral fragment. If this is successful, the participant will be excluded from the study and deemed an intra-operative screen failure. If the attempted reattachment fails and no other exclusion criteria apply, the participant may continue in the PEAK study: a MACI biopsy will be taken, the participant will be randomized and treated per protocol.

• At least 1 defect size ≥1.5 cm2 on the patella, femoral condyles and/or the trochlea; defects include OCD lesions with a bone lesion depth of ≤6 mm and does not require a bone graft.

• Salvageable OCD lesions must have failed prior conservative and a reparative treatment, and the participant still experiences pain associated with the osteochondral lesion. Participants with defects as a result of trauma or unknown etiology are eligible regardless of prior treatments.

• Stable target knee (i.e., anterior and posterior cruciate ligaments should be free of laxity as well as stable and intact). Ligament repair or reconstruction procedures are allowed prior to screening arthroscopy.

• Intact meniscus or partial meniscus (at least 50% of functional meniscus remaining) in the target knee. Meniscal repair or resection might be performed either staged or concurrent with the cartilage repair procedure provided that the surgeon was able to confirm that at least 50% of functional meniscus would remain after the corrective meniscal treatment.

• Written informed consent

Locations
United States
California
Stanford University
RECRUITING
Palo Alto
Shriner's Hospital for Children Northern California
RECRUITING
Sacramento
University of California Davis Health
RECRUITING
Sacramento
Louisiana
Ochsner Sports Medicine Institute
RECRUITING
New Orleans
Maryland
Johns Hopkins Outpatient Center
RECRUITING
Baltimore
Michigan
University of Michigan
RECRUITING
Ann Arbor
Ohio
Akron Children's Hospital
RECRUITING
Akron
The Ohio State University Jameson Crane Sports Medicine Institute
RECRUITING
Columbus
Pennsylvania
Children's Hospital of Philadelphia
RECRUITING
Philadelphia
Penn Sports Medicine Center
RECRUITING
Philadelphia
Texas
Texas Children's Hospital
WITHDRAWN
Houston
Wisconsin
Medical College of Wisconsin
RECRUITING
Milwaukee
Contact Information
Primary
Vericel Clinical Affairs
clinicalhotline@vcel.com
978-347-2876
Time Frame
Start Date: 2018-10-24
Estimated Completion Date: 2030-02
Participants
Target number of participants: 45
Treatments
Experimental: MACI
autologous cultured chondrocytes on porcine collagen membrane
Other: microfracture
surgical procedure
Related Therapeutic Areas
Sponsors
Leads: Vericel Corporation

This content was sourced from clinicaltrials.gov